A case series of 11 MPN patients published in 2018 with multiple driver mutations (including BCR-ABL) had 8 patients positive for BCR-ABL and JAK2 V617F mutations, 1 patient positive for BCR-ABL and CALR type 2 mutations, and 2 patients (referenced in Table 1) negative for Philadelphia chromosome, and one each among them had JAK2 V617F + MPL, JAK2 V617F, and CALR mutations [22]. Here, JAK2 is linked to myeloproliferative neoplasm.